According to the New York Times (NYT) a week ago, a major new study found that lower doses of antipsychotics are better for the treatment of schizophrenia:
The paper, by John M. Kane and colleagues and published in the American Journal of Psychiatry (AJP), is called Comprehensive Versus Usual Community Care for First-Episode Psychosis and it presents the results of the NIMH “RAISE” study.
It’s an impressive paper. However, it’s not a paper about dose reduction. So the NYT‘s coverage was misleading.
The word “dose” (including variants such as “dosage”) appears just once in the Kane et al. paper, and that’s in reference to other studies, not the current one.
Three days ago the NYT accordingly issued a correction:
An article on Tuesday about a study of the treatment of first-episode schizophrenia referred incorrectly to the conclusions of the study. Though it studied a program intended to reduce medication dosages, the researchers do not yet know for sure if dosages were lowered or by how much.
Therefore, the study did not conclude “that schizophrenia patients who received smaller doses of antipsychotic medication and a bigger emphasis on one-on-one talk therapy and family support made greater strides in recovery.”
REad the full story here: